( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .



    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019


    MAY 2023 Issue has been successfully launched on 1 MAY 2023.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR May 2023 Issue has been Published, Kindly check it on

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here




*Rama Khaddour, Lena Ramadan and Loai Hasan


Background: Fibroids are considered the most common benign pelvic tumor in women, and they arise at the expense of smooth muscle fibers interspersed with connective tissue. They may be symptomatic or asymptomatic, and the severity and quality of symptoms vary according to the location, size, and number of the fibroids, and they need treatment only if they cause symptoms. Objective: Main objective: To compare the clinical and echogenic efficacy of treatment with letrozole and synthetic progestins in the management of fibroids. Second objective: to reduce the use of surgical operations to remove fibroids, and thus reduce the complications resulting from them. Materials and methods: This study is a prospective study that included reviews with clinical symptoms of echogenic fibroids, especially with complaints of menstrual bleeding during the period from March 2022 and March 2023, where the women were divided into two groups: the first was treated with letrozole 2.5 mg daily continuously for 12 weeks. the second treated with progestin (medroxyprogesterone acetate) 150 mg as a single dose for 3 months, and studied the clinical improvement through the decrease in the intensity of menstrual bleeding or dysmenorrhoea and the echo change in the size of the fibroid tumer as a result of treatment, and it was compared between the two groups. The letrozole group included 27 patients and the progestin group 23 patients. Results: The average age of women in the study was (44.15 years), and the average size of the fibroid tumor in the letrozole group was 3.44 cm compared to 3.32 cm in the progestin group. The size of the echogenic fibroid decreased by 42.1% in 85.2% of the letrozole-treated patients and 24.1% in the progestin-treated patients, of while the size remained constant in 7,4% of the letrozole group and 30,4% of the progestins group, and its volume increased in 7,4% of the letrozole group and 17,4% of the progestins group, with a stst Clinically, menstrual bleeding decreased in 85,2% of the letrozole group compared to 82,6% of the progestin group, without a statistically significant difference. Conclusion: Clinical and echogenic improvement was statistically significant in the letrozole and synthetic progestins groups, with letrozole being statistically significantly superior to progestins in echogenic terms. Therefore, it is recommended to conduct more extensive clinical studies on this benefit in preparation for taking it as a conservative treatment in specific cases of fibroids, especially those associated menorrhagia.

[Full Text Article]